Subendothelial retention of atherogenic lipoproteins in early atherosclerosis.
Complications of atherosclerosis are the most common cause of death in Western societies. Among the many risk factors identified by epidemiological studies, only elevated levels of lipoproteins containing apolipoprotein (apo) B can drive the development of atherosclerosis in humans and experimental animals even in the absence of other risk factors. However, the mechanisms that lead to atherosclerosis are still poorly understood. We tested the hypothesis that the subendothelial retention of atherogenic apoB-containing lipoproteins is the initiating event in atherogenesis. The extracellular matrix of the subendothelium, particularly proteoglycans, is thought to play a major role in the retention of atherogenic lipoproteins. The interaction between atherogenic lipoproteins and proteoglycans involves an ionic interaction between basic amino acids in apoB100 and negatively charged sulphate groups on the proteoglycans. Here we present direct experimental evidence that the atherogenicity of apoB-containing low-density lipoproteins (LDL) is linked to their affinity for artery wall proteoglycans. Mice expressing proteoglycan-binding-defective LDL developed significantly less atherosclerosis than mice expressing wild-type control LDL. We conclude that subendothelial retention of apoB100-containing lipoprotein is an early step in atherogenesis.
Skålén
Kristina
K
Wallenberg Laboratory for Cardiovascular Research, Göteborg University, Göteborg S-4345, Sweden.
Gustafsson
Maria
M
Rydberg
Ellen Knutsen
EK
Hultén
Lillemor Mattsson
LM
Wiklund
Olov
O
Innerarity
Thomas L
TL
Borén
Jan
J
D019943:Amino Acid Substitution; D000818:Animals; D001011:Aorta; D053299:Apolipoprotein B-100; D001055:Apolipoproteins B / Q000097:blood / Q000235:genetics / Q000378:metabolism; D001161:Arteriosclerosis / Q000097:blood* / Q000209:etiology / Q000378:metabolism* / Q000473:pathology; D001667:Binding, Competitive; D002784:Cholesterol / Q000097:blood / Q000378:metabolism; D004036:Diet, Atherogenic; D004730:Endothelium, Vascular / Q000378:metabolism*; D005260:Female; D006801:Humans; D008074:Lipoproteins / Q000097:blood* / Q000378:metabolism*; D008077:Lipoproteins, LDL / Q000097:blood / Q000235:genetics / Q000378:metabolism; D008264:Macrophages / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D008954:Models, Biological; D009154:Mutation; D011973:Receptors, LDL / Q000097:blood / Q000378:metabolism; D011994:Recombinant Proteins / Q000378:metabolism; D014280:Triglycerides / Q000097:blood / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D053299:Apolipoprotein B-100; D001055:Apolipoproteins B; D008074:Lipoproteins; D008077:Lipoproteins, LDL; D011973:Receptors, LDL; D011994:Recombinant Proteins; D014280:Triglycerides; D014409:Tumor Necrosis Factor-alpha; D002784:Cholesterol